News from Wednesday, November 27, 2024
Articles
Risankizumab Has Higher Skin Clearance, QOL Than Deucravacitinib in Psoriasis
(11/27, Ron Goldberg, Dermatology Advisor) reports “In an indirect comparison, risankizumab may have higher rates of skin clearance and greater improvements in quality of life (QOL) in patients with moderate to severe psoriasis (PsO) when compared with deucravacitinib, according to study findings published in Dermatology and Therapy.” Full
Biosimilar vs Bio-Originator Infliximab and Etanercept Show Similar Infection Rates
(11/27, Hibah Khaja, PharmD, Rheumatology Advisor) reports “The incidence of serious infection among patients receiving infliximab and etanercept biosimilars is comparable to that of their bio-originator products, according to study results published in BMC Rheumatology.” Full
Proposed Rule Addresses Formulary Placement, Drug Negotiation & OOP Payment Plan
(11/26, Gabrielle Wanneh, Maaisha Osman, InsideHealthPolicy) reports “...CMS clarifies that Part D plan sponsors must provide enrollees with broad access to generics, biosimilars and any other lower-cost drugs in order to fully comply with the statutory requirement to establish and maintain a cost-effective drug utilization management program that includes incentives to reduce costs when medically appropriate. CMS hopes to curb practices used by plans and PBMs that favor expensive brand drugs and reference biologics over more affordable alternatives in terms of formulary placement or non-placement, leading to higher out-of-pocket drug costs for beneficiaries.” Subscription Required
Real-World Evidence Trials Set to Increase for 2024
(11/27, GlobalData, Clinical Trials Arena) reports “...For 2024, the current number of RWE trials stands at 331 trials and is set to surpass 336 trials as the year is still ongoing. According to an analysis of the different trial statuses of RWE trials, 53.9% of trials were completed, 22.1% of trials were ongoing and recruiting, 8.1% of trials were planned, 7.0% of trials were ongoing but not recruiting, and 8.2% of trials were suspended/terminated/withdrawn (S/T/W).” Full
Press Releases
New Joint Guideline Recommends Prescribing Combination Treatments for People with Newly Diagnosed Asthma
(11/27, NICE Press Release) “...For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have worked together to produce a new UK-wide joint guidance for the diagnosis and management of chronic asthma in adults, young people and children. It recommends healthcare practitioners should offer a low-dose combination of inhaled corticosteroids (ICS) and formoterol to be taken as needed for everyone aged 12 and over with newly diagnosed asthma to reduce inflammation as well as relieve symptoms.” Full
Journals
Comparative Efficacy of Different Pharmacological Treatments for Pityriasis Rosea: A Network Meta-Analysis
Giulia Ciccarese, et al.
November 6, 2024, Journal of Clinical Medicine
The Use of Patient-Reported Outcome Measures to Improve Patient-Related Outcomes – A Systematic Review
Joshua M. Bonsel, et al.
November 26, 2024, Health and Quality of Life Outcomes